Abstract
There is an immense diversity of marine plants and animals from which an estimated 14,000 pharmacologically active compounds have been isolated. However, in terms of clinically useful anti-cancer agents, the oceans remain as a largely untapped resource. Indeed, there are currently only two compounds used in the clinic that are derived from marine sources. These are cytarabine, which is a deoxycitidine analogue and aplidine, which has both growth inhibitory and anti-angiogenic effects. This situation is likely to change rather dramatically in the near future, as attention has focused on the vast diversity of available agents from marine organisms. The increased pace of activity in this area has resulted in a several clinical trials of promising compounds with the probability that these will be followed by other drugs currently under preclinical development.
Keywords: Aplidine, Ascididemin, Protein kinase C, cephalostatins, Dideoxypetrosynol A
Current Pharmaceutical Design
Title: Novel Marine-Derived Anti-Cancer Agents
Volume: 13 Issue: 33
Author(s): Thomas E. Adrian
Affiliation:
Keywords: Aplidine, Ascididemin, Protein kinase C, cephalostatins, Dideoxypetrosynol A
Abstract: There is an immense diversity of marine plants and animals from which an estimated 14,000 pharmacologically active compounds have been isolated. However, in terms of clinically useful anti-cancer agents, the oceans remain as a largely untapped resource. Indeed, there are currently only two compounds used in the clinic that are derived from marine sources. These are cytarabine, which is a deoxycitidine analogue and aplidine, which has both growth inhibitory and anti-angiogenic effects. This situation is likely to change rather dramatically in the near future, as attention has focused on the vast diversity of available agents from marine organisms. The increased pace of activity in this area has resulted in a several clinical trials of promising compounds with the probability that these will be followed by other drugs currently under preclinical development.
Export Options
About this article
Cite this article as:
Adrian E. Thomas, Novel Marine-Derived Anti-Cancer Agents, Current Pharmaceutical Design 2007; 13 (33) . https://dx.doi.org/10.2174/138161207782360500
DOI https://dx.doi.org/10.2174/138161207782360500 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CDK-associated Cullin 1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Human Glioblastoma
Current Cancer Drug Targets Meet Our Editorial Board Member
Recent Patents on Inflammation & Allergy Drug Discovery HSP60 as a Drug Target
Current Pharmaceutical Design Clonetics
Current Drug Metabolism Genetic Chemoprotection with Mutant O6-Alkylguanine-DNA-Alkyltransferases
Current Gene Therapy WISP1 (CCN4) Autoregulates its Expression and Nuclear Trafficking of β-Catenin during Oxidant Stress with Limited Effects upon Neuronal Autophagy
Current Neurovascular Research Development of 96-microwell Plate Assay with Fluorescence Reader and HPLC Method with Fluorescence Detection for High-throughput Analysis of Linifanib in its Bulk and Dosage Forms
Current Pharmaceutical Analysis Nanoparticles: A Neurotoxicological Perspective
CNS & Neurological Disorders - Drug Targets Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous
Current Cancer Drug Targets EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease
Current Alzheimer Research Retinoid Related Molecules an Emerging Class of Apoptotic Agents with Promising Therapeutic Potential in Oncology: Pharmacological Activity and Mechanisms of Action
Current Pharmaceutical Design Modifications of Cell Signalling and Redox Balance by Targeting Protein Acetylation Using Natural and Engineered Molecules: Implications in Cancer Therapy
Current Topics in Medicinal Chemistry CNS Immune Surveillance and Neuroinflammation: Endocannabinoids Keep Control
Current Pharmaceutical Design Expression of Opioid Receptors During Peripheral Inflammation
Current Topics in Medicinal Chemistry Resveratrol: A New Potential Therapeutic Agent for Melanoma?
Current Medicinal Chemistry Spermine Metabolism and Anticancer Therapy
Current Cancer Drug Targets Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Current Drug Therapy